Ridaforolimus in advanced or metastatic soft tissue and bone sarcomas.

about

Emerging therapies for adult soft tissue sarcoma.Bone Sarcomas in Pediatrics: Progress in Our Understanding of Tumor Biology and Implications for Therapy.Recent Advances and Challenges of mTOR Inhibitors Use in the Treatment of Patients with Tuberous Sclerosis Complex.

P2860

Q34659806-6899D7A4-B3EE-4B01-A7AD-A99910DA2A15 Q35894540-52D104E5-1256-4C03-8B58-2284003B1FB4 Q37721031-54F2060E-DF62-4A25-A7DD-2CA3AE1E9567

P2860

Ridaforolimus in advanced or metastatic soft tissue and bone sarcomas.

Item

http://www.wikidata.org/entity/Q38131047

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Ridaforolimus in advanced or metastatic soft tissue and bone sarcomas.

@en

type

Item

label

Ridaforolimus in advanced or metastatic soft tissue and bone sarcomas.

@en

prefLabel

Ridaforolimus in advanced or metastatic soft tissue and bone sarcomas.

@en

P1476

Ridaforolimus in advanced or metastatic soft tissue and bone sarcomas.

@en

P2093

Jun Gong

http://www.w3.org/2001/XMLSchema#string

Monica M Mita

http://www.w3.org/2001/XMLSchema#string

Sant P Chawla

http://www.w3.org/2001/XMLSchema#string

P2860

Pushing the envelope in the mTOR pathway: the second generation of inhibitors

Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle

Current development of mTOR inhibitors as anticancer agents

Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer.

A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas.

Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma

Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors.

Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

A phase I study of sirolimus and bevacizumab in patients with advanced malignancies.

P304

465-482

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/17512433.2013.827397

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-08-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23971829

http://www.w3.org/2001/XMLSchema#string

Ridaforolimus in advanced or metastatic soft tissue and bone sarcomas.

about

P2860

P2860

Ridaforolimus in advanced or metastatic soft tissue and bone sarcomas.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698